80 related articles for article (PubMed ID: 7121879)
1. [Effect of antiblastic polychemotherapy (CMF) on the number of circulating monocytes in patients with breast cancer].
Bariani L; Dolcetti U; Indelli M; Gualandi G; Malacarne P; Castaldi G
Minerva Med; 1982 Oct; 73(39):2641-8. PubMed ID: 7121879
[TBL] [Abstract][Full Text] [Related]
2. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of advanced breast cancer with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone (CMFP)].
Rabinovich MG; Leone BA; Landó O
Medicina (B Aires); 1981; 41(1):65-70. PubMed ID: 7266359
[No Abstract] [Full Text] [Related]
4. [Adjuvant endocrine therapy and chemotherapy of breast cancer (author's transl)].
Heuson JC; Paridaens R
Rev Med Brux; 1982 Apr; 3(4):209-16. PubMed ID: 7046007
[No Abstract] [Full Text] [Related]
5. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
Sverrisdottir A; Nystedt M; Johansson H; Fornander T
Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
[TBL] [Abstract][Full Text] [Related]
6. [Polychemotherapy of advanced cancer of the breast].
Mascia V; Massidda B; Pellegrini A
Minerva Med; 1978 May; 69(26):1803-8. PubMed ID: 662182
[TBL] [Abstract][Full Text] [Related]
7. Actual data on efficacy of surgical adjuvant chemotherapy with CMF in breast cancer.
Bonadonna G; Rossi A; Valagussa P; Veronesi U
Arch Geschwulstforsch; 1978; 48(7):659. PubMed ID: 736746
[No Abstract] [Full Text] [Related]
8. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
[TBL] [Abstract][Full Text] [Related]
9. [Results of "5-drug" treatment of advanced breast cancer].
Dorociak R
Pol Tyg Lek; 1981 Sep; 36(38):1467-70. PubMed ID: 7329862
[No Abstract] [Full Text] [Related]
10. [Randomized comparative study of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and UFT-tamoxifen regimens as adjuvant chemotherapy after surgery for breast cancer: Tochigi Prefectural Study Group for Post-Breast Cancer Adjuvant Chemotherapy].
Tamura H; Kojima M; Kobayashi H; Ando J; Oka S; Fujisaki M; Wada N; Imoto S; Ikeda T
Gan To Kagaku Ryoho; 2000 Jul; 27(7):993-1002. PubMed ID: 10925684
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
13. [Preoperative polychemotherapy in the overall treatment of locally spread breast cancer (immediate results)].
Sokolova IG; Vishniakova EG; Sviatukhina OV
Vopr Onkol; 1980; 26(5):9-13. PubMed ID: 7385720
[TBL] [Abstract][Full Text] [Related]
14. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
15. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
Pierce LJ; Hutchins LF; Green SR; Lew DL; Gralow JR; Livingston RB; Osborne CK; Albain KS
J Clin Oncol; 2005 Jan; 23(1):24-9. PubMed ID: 15545669
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
18. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
[TBL] [Abstract][Full Text] [Related]
19. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
Gordon NH; Silverman P; Lasheen W; Meinert J; Siminoff LA
Breast Cancer Res Treat; 2007 May; 102(3):301-12. PubMed ID: 17033926
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
